An FDA advisory committee voted 16-0 to recommend Moderna's mRNA-based influenza vaccine. This unanimous endorsement signals a high likelihood of full FDA approval.
The decision validates Moderna's underlying mRNA technology platform, which has numerous other vaccines and therapies in development.
Moderna (MRNA) shares surged over 10% following the July 2nd announcement. The healthcare sector climbed 2.7% to become the day's top-performing sector.
This development marks a crucial step for Moderna in expanding its product line beyond COVID-19 boosters. It solidifies the company's competitive position in the respiratory vaccine market.